Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13528594 | 0.87 | HTR2A (0.39) | ADRA2ALMNAKDM4EALDH1A1 | |
| SCHEMBL3175071 | 0.85 | ALDH1A1 (0.44) | TRPA1LMNAALDH1A1 | |
| SCHEMBL17862086 | 0.83 | HCAR2 (0.38) | HCAR2ADRA2AADRA2CADRA2BTAAR1 | |
| SCHEMBL15302056 | 0.79 | HCAR2 (0.41) | HCAR2ADRA2AADRA2CADRA2BTAAR1 | |
| SCHEMBL3888063 | 0.79 | ALDH1A1 (0.35) | TAAR1TRPA1LMNAALDH1A1 | |
| SCHEMBL13528585 | 0.79 | THRB (0.37) | ADRA2AADRA2CTAAR1TRPA1CYP2D6 | |
| SCHEMBL23701039 | 0.76 | TRPA1 (0.32) | TAAR1TRPA1 | |
| SCHEMBL23701156 | 0.76 | TSHR (0.33) | — | |
| SCHEMBL1025648 | 0.76 | HCAR2 (0.43) | HCAR2ADRA2AADRA2CADRA2BTAAR1 | |
| SCHEMBL4622367 | 0.76 | HCAR2 (0.39) | HCAR2ADRA2AADRA2CADRA2BTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066601-B1 | HYDROSILYLATION | AGENCY SCIENCE TECH & RES (SG) | 2012-10-24 | — | — | EP | disclosed |
| US-20100016621-A1 | Hydrosilylation | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-01-21 | — | — | US | disclosed |
| US-20100016621-A1 | Hydrosilylation | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-01-21 | — | — | US | disclosed |
| EP-2066601-A1 | HYDROSILYLATION | Agency for Science, Technology And Research (SG) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008039154-A1 | HYDROSILYLATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016621-A1 | Hydrosilylation | HACL2, HAO2, VIM | HCAR2 1588/4885ADRA2A 2841/4885ADRA2C 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.